RDUS - Radius Health jumps 14% on $890M buyout offer

The shares of Radius Health (NASDAQ:RDUS) surged 14% in the morning hours Thursday after the commercial stage biotech announced an agreement under which y Gurnet Point Capital and Patient Square Capital will acquire the company for $890M. The valuation includes the assumption of debt and the full payment of the CVR (Contingent Value Right) based on a sales target for osteoporosis drug TYMLOS (abaloparatide). Per the terms, an entity co-owned by Gurnet Point and Patient Square will start a tender offer to acquire all of the outstanding shares of Radius Health (RDUS) for $10.00 in cash plus a CVR of $1.00 per share. The CVR is subject to $300M TYMLOS net sales during any consecutive 12-month period prior to December 31, 2025. Agreement indicates that the shareholders of Radius Health (RDUS) are set to receive $547M in cash including the CVR payment. The upfront payment implies a premium of 45% over the

For further details see:

Radius Health jumps 14% on $890M buyout offer